Company Highlights

Welcome to Patrys

Patrys is a publicly-listed company on the Australian Securities Exchange (ASX:PAB).  Our principal focus is on the development of antibody therapies for major market opportunities in the oncology area.  Patrys has two technology platforms: IgM monoclonal antibodies and suite of nuclear penetrating antibodies for cancer therapy.   

Welcome Picture re design

Latest News

Audio Gallery

Dr. James Campbell
CEO - Manufacturing Update
12 June 2015

Listen online

Search Patrys


Follow Us on Media